Compare Stocks: NVO, JNJ, MRK, and NVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$259.65 +0.2%	$248.47	$171.81 ▼ $274.90	$625.60B	0.24	8.36 million shs	3.44 million shs
MRK Merck & Co., Inc.	$130.67 +1.6%	$123.98	$77.58 ▼ $135.05	$322.71B	0.19	10.72 million shs	2.35 million shs
NVO Novo Nordisk A/S	$47.11 -0.3%	$47.00	$35.12 ▼ $64.16	$210.32B	0.76	18.15 million shs	5.88 million shs
NVS Novartis	$156.22 -0.1%	$152.99	$117.54 ▼ $170.46	$298.03B	0.45	1.97 million shs	561,680 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	0.00%	+0.98%	+0.72%	+17.02%	+49.38%
MRK Merck & Co., Inc.	0.00%	-1.44%	+3.95%	+15.37%	+59.31%
NVO Novo Nordisk A/S	0.00%	+0.01%	-4.61%	+1.88%	-7.55%
NVS Novartis	0.00%	+0.13%	+1.51%	+7.77%	+33.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$259.65 +0.2%	$248.47	$171.81 ▼ $274.90	$625.60B	0.24	8.36 million shs	3.44 million shs
MRK Merck & Co., Inc.	$130.67 +1.6%	$123.98	$77.58 ▼ $135.05	$322.71B	0.19	10.72 million shs	2.35 million shs
NVO Novo Nordisk A/S	$47.11 -0.3%	$47.00	$35.12 ▼ $64.16	$210.32B	0.76	18.15 million shs	5.88 million shs
NVS Novartis	$156.22 -0.1%	$152.99	$117.54 ▼ $170.46	$298.03B	0.45	1.97 million shs	561,680 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	0.00%	+0.98%	+0.72%	+17.02%	+49.38%
MRK Merck & Co., Inc.	0.00%	-1.44%	+3.95%	+15.37%	+59.31%
NVO Novo Nordisk A/S	0.00%	+0.01%	-4.61%	+1.88%	-7.55%
NVS Novartis	0.00%	+0.13%	+1.51%	+7.77%	+33.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.80	Moderate Buy	$268.22	3.30% Upside
MRK Merck & Co., Inc.	2.65	Moderate Buy	$134.56	2.98% Upside
NVO Novo Nordisk A/S	2.19	Hold	$65.81	39.71% Upside
NVS Novartis	2.31	Hold	$141.20	-9.61% Downside

Current Analyst Ratings Breakdown

Latest NVO, JNJ, MRK, and NVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	NVO Novo Nordisk A/S	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform	$47.00
8/6/2026	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$270.00 ➝ $287.00
8/5/2026	NVO Novo Nordisk A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/5/2026	MRK Merck & Co., Inc.	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $146.00
8/3/2026	JNJ Johnson & Johnson	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$280.00
8/3/2026	JNJ Johnson & Johnson	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	JNJ Johnson & Johnson	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$272.00 ➝ $282.00
7/29/2026	JNJ Johnson & Johnson	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$300.00
7/29/2026	MRK Merck & Co., Inc.	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$140.00 ➝ $150.00
7/24/2026	JNJ Johnson & Johnson	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
7/24/2026	NVS Novartis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$97.93B	6.39	$14.14 per share	18.36	$33.85 per share	7.67
MRK Merck & Co., Inc.	$65.01B	4.96	$11.60 per share	11.26	$21.22 per share	6.16
NVO Novo Nordisk A/S	$46.80B	4.49	$4.67 per share	10.08	$6.58 per share	7.16
NVS Novartis	$54.53B	5.47	$10.73 per share	14.56	$22.04 per share	7.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$26.80B	$8.63	30.08	20.28	2.47	21.48%	32.42%	13.35%	10/13/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$1.25	104.53	13.51	5.56	4.77%	16.05%	6.11%	10/29/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.09	11.52	14.15	4.31	35.36%	61.20%	21.49%	N/A
NVS Novartis	$13.98B	$6.63	23.56	15.92	2.67	23.29%	38.56%	14.47%	10/27/2026 (Estimated)

Latest NVO, JNJ, MRK, and NVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.96	+$0.19	$0.72	$10.89 billion	$11.98 billion
8/4/2026	Q2 2026	MRK Merck & Co., Inc.	-$0.26	-$0.13	+$0.13	-$0.54	$16.37 billion	$16.61 billion
7/21/2026	Q2 2026	NVS Novartis	$2.17	$2.41	+$0.24	$1.71	$14.07 billion	$14.41 billion
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion
6/30/2026	Q2 2026	NVO Novo Nordisk A/S	N/A	$0.9440	N/A	$0.72	N/A	$11.98 billion
6/30/2026	Q2 2026	NVS Novartis	N/A	$2.41	N/A	$1.71	N/A	$14.95 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.36	2.06%	+5.25%	62.11%	64 Years
MRK Merck & Co., Inc.	$3.40	2.60%	+5.75%	272.00%	14 Years
NVO Novo Nordisk A/S	$1.75	3.72%	+21.74%	42.79%	N/A
NVS Novartis	$3.08	1.97%	+5.28%	46.46%	N/A

Latest NVO, JNJ, MRK, and NVS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.61%	9/15/2026	9/15/2026	10/7/2026
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.17%	8/25/2026	8/25/2026	9/8/2026
8/5/2026	NVO Novo Nordisk A/S		$0.5786	2.54%	8/17/2026	8/17/2026	8/25/2026
5/26/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.96%	6/15/2026	6/15/2026	7/8/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.44	1.09	0.81
MRK Merck & Co., Inc.	1.02	1.30	1.06
NVO Novo Nordisk A/S	0.59	0.79	0.56
NVS Novartis	0.89	0.86	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
MRK Merck & Co., Inc.	76.07%
NVO Novo Nordisk A/S	11.54%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
MRK Merck & Co., Inc.	0.17%
NVO Novo Nordisk A/S	0.07%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.47 billion	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable

NVO, JNJ, MRK, and NVS Headlines

Recent News About These Companies

Novartis AG Sponsored ADR

August 9 at 8:47 AM | cnn.com

Zacks Research Comments on Novartis' Q3 Earnings (NYSE:NVS)

August 7 at 1:13 AM | americanbankingnews.com

The Manufacturers Life Insurance Company Sells 24,216 Shares of Novartis AG $NVS

August 6, 2026 | marketbeat.com

Research Analysts Offer Predictions for Novartis Q3 Earnings

August 5, 2026 | marketbeat.com

Segall Bryant & Hamill LLC Purchases Shares of 18,792 Novartis AG $NVS

August 5, 2026 | marketbeat.com

Glenmede Trust Co. NA Acquires 8,680 Shares of Novartis AG $NVS

August 4, 2026 | marketbeat.com

FDA approval nearly doubles eligible patient pool for Novartis' Pluvicto

August 3, 2026 | msn.com

Novartis AG $NVS Shares Sold by Public Employees Retirement System of Ohio

August 3, 2026 | marketbeat.com

Henshaw Capital LLC Grows Stock Position in Novartis AG $NVS

August 2, 2026 | marketbeat.com

FY2026 EPS Estimates for Novartis Raised by Erste Group Bank

August 2, 2026 | americanbankingnews.com

Novartis AG $NVS Shares Purchased by Royal Bank of Canada

August 1, 2026 | marketbeat.com

Bank of America Corp DE Raises Stock Holdings in Novartis AG $NVS

August 1, 2026 | marketbeat.com

Erste Group Bank Forecasts Increased Earnings for Novartis

July 31, 2026 | marketbeat.com

Novartis AG $NVS Shares Bought by Janus Henderson Group PLC

July 31, 2026 | marketbeat.com

Novartis AG $NVS Shares Bought by Empowered Funds LLC

July 31, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Sells 679,380 Shares of Novartis AG $NVS

July 31, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Novartis (NVS) and NeoGenomics (NEO)

July 30, 2026 | theglobeandmail.com

Quantinno Capital Management LP Acquires 39,537 Shares of Novartis AG $NVS

July 30, 2026 | marketbeat.com

Ashton Thomas Securities LLC Makes New Investment in Novartis AG $NVS

July 30, 2026 | marketbeat.com

Novartis chart may soon 'complete a well-defined bullish reversal,' Cappelleri says

July 29, 2026 | cnbc.com

Novartis AG $NVS Shares Sold by Family Manage LLC

July 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVO, JNJ, MRK, and NVS Company Descriptions

Johnson & Johnson NYSE:JNJ

$259.64 +0.41 (+0.16%)

As of 02:27 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. NYSE:MRK

$130.67 +2.09 (+1.62%)

As of 02:27 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S NYSE:NVO

$47.10 -0.16 (-0.33%)

As of 02:27 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novartis NYSE:NVS

$156.22 -0.11 (-0.07%)

As of 02:27 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVO, JNJ, MRK, and NVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVO, JNJ, MRK, and NVS Earnings

Compare Dividends

Latest NVO, JNJ, MRK, and NVS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVO, JNJ, MRK, and NVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVO, JNJ, MRK, and NVS Company Descriptions

Johnson & Johnson NYSE:JNJ

Merck & Co., Inc. NYSE:MRK

Novo Nordisk A/S NYSE:NVO

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools